Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review
AbstractLangerhans cell histiocytosis (LCH) is a histiocytic neoplasm characterized by a mass of CD1a + CD207 + histiocytes, exhibiting a diverse range of clinical manifestations from a self-healing rash or single bone destruction to multi-organ disease with potentially fatal consequences. The ident...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
Taylor & Francis Group,
2023-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_3dbb27560c9c4b25a9fbd09f7bafccf0 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Qingqing Li |e author |
| 245 | 0 | 0 | |a Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review |
| 260 | |b Taylor & Francis Group, |c 2023-12-01T00:00:00Z. | ||
| 500 | |a 10.1080/09546634.2023.2279901 | ||
| 500 | |a 1471-1753 | ||
| 500 | |a 0954-6634 | ||
| 520 | |a AbstractLangerhans cell histiocytosis (LCH) is a histiocytic neoplasm characterized by a mass of CD1a + CD207 + histiocytes, exhibiting a diverse range of clinical manifestations from a self-healing rash or single bone destruction to multi-organ disease with potentially fatal consequences. The identification of MAPK signaling pathway activation, particularly BRAFV600E mutations, has propelled targeted therapy into the forefront of therapeutic research for LCH. Several studies have demonstrated that Vemurafenib, a BRAF inhibitor, exhibits superior clinical efficacy and a more favorable safety profile in LCH. Herein, in this case report, we present a good response to vemurafenib in an infant diagnosed with multisystem Langerhans cell histiocytosis (LCH). | ||
| 546 | |a EN | ||
| 690 | |a Langerhans cell histiocytosis | ||
| 690 | |a vemurafenib | ||
| 690 | |a infant | ||
| 690 | |a treatment | ||
| 690 | |a Dermatology | ||
| 690 | |a RL1-803 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Journal of Dermatological Treatment, Vol 34, Iss 1 (2023) | |
| 787 | 0 | |n https://www.tandfonline.com/doi/10.1080/09546634.2023.2279901 | |
| 787 | 0 | |n https://doaj.org/toc/0954-6634 | |
| 787 | 0 | |n https://doaj.org/toc/1471-1753 | |
| 856 | 4 | 1 | |u https://doaj.org/article/3dbb27560c9c4b25a9fbd09f7bafccf0 |z Connect to this object online. |